CAMBRIDGE, UNITED KINGDOM--(Marketwire - February 19, 2008) - BioWisdom Ltd, the market leader in ontology-powered intelligence solutions for the healthcare industry, today announced a three-year agreement with Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, NV (J&JPRD).

Under the terms of the agreement, J&JPRD will become the second partner for BioWisdom's Safety Intelligence Program (SIP). The first partnership was formed with AstraZeneca. The financial details of the deal have not been disclosed.

The Safety Intelligence Program applies BioWisdom's Sofia technology to deliver a specialist medical search system to support drug safety risk assessment at all stages of pharmaceutical R&D. Through the partnership, J&JPRD joins BioWisdom's SIP board.

"We are delighted to have J&JPRD join our Safety Intelligence Program and look forward to working closely with safety assessment teams across the organisation and affiliates" said Dr. Julie Barnes, Chief Scientific Officer of BioWisdom. "This second partnership is a testimony to the value that the pharmaceutical industry sees in our approach to drug safety and risk management."

Dr Jack Reynolds, Chairman of the SIP Board said, "I am delighted to see the relationship between BioWisdom and J&JPRD established. I look forward to working with all partners on the SIP Board to advance the Safety Intelligence Program for the purpose of improving our understanding of many of the major recurring and potentially serious drug-induced adverse events."

Notes to Editors

ABOUT BIOWISDOM
BioWisdom delivers intelligence solutions for the Healthcare Industry and helps clients to navigate the complex scientific and commercial issues involved in developing successful healthcare products. The company provides a powerful suite of software tools for format, search, visualization and high value analysis of healthcare intelligence. The BioWisdom team combines extensive experience of the pharmaceutical industry with proven expertise in life science software development.

For further information please visit www.biowisdom.com.